Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., specializes in providing custom research and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Group 1: Business Overview - The main business involves providing small molecule drug intermediates and custom R&D production services for new drug development projects [2][8]. - The company has launched projects for pharmaceutical intermediates, including the oral formulation absorption enhancer SNAC for Semaglutide [2][3]. - As of the 2024 annual report, overseas revenue accounts for 61.18% of total revenue, benefiting from the depreciation of the RMB [4]. Group 2: Financial Performance - For the first half of 2025, the company achieved operating revenue of 348 million yuan, representing a year-on-year growth of 32.98%, and a net profit attributable to shareholders of 71.76 million yuan, up 123.61% year-on-year [8]. - Since its A-share listing, the company has distributed a total of 117 million yuan in dividends [9]. Group 3: Market Activity - On September 4, the company's stock price decreased by 0.28%, with a trading volume of 170 million yuan and a turnover rate of 7.65%, resulting in a total market capitalization of 4.66 billion yuan [1]. - The stock has seen a net inflow of 7.47 million yuan from major investors today, with no significant trend in major holdings [5][6].
金凯生科跌0.28%，成交额1.70亿元，今日主力净流入746.54万